{"title":"冠状病毒病19 (COVID-19)的药物治疗","authors":"N. Bogdanić, L. Lukić, J. Begovac","doi":"10.37797/ig.40.4.4","DOIUrl":null,"url":null,"abstract":"Since the first cases of COVID-19 were reported from China the disease became pandemic within a few months. The viral genome was sequenced soon after the outbreak of COVID-19 which enabled development of diagnostic tests and therapeutic options. As the knowledge of SARS-CoV-2 virology increased, many potential drugs appeared. At this moment (January 12th 2021), 4426 studies of COVID-19 are registered, and more than 2680 studies are investigating therapeutic options. This is a short narrative review of currently available evidence on pharmacological treatment of COVID-19.","PeriodicalId":354348,"journal":{"name":"Infektološki glasnik","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Coronavirus Disease 19 (COVID-19) Pharmacologic Treatment\",\"authors\":\"N. Bogdanić, L. Lukić, J. Begovac\",\"doi\":\"10.37797/ig.40.4.4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Since the first cases of COVID-19 were reported from China the disease became pandemic within a few months. The viral genome was sequenced soon after the outbreak of COVID-19 which enabled development of diagnostic tests and therapeutic options. As the knowledge of SARS-CoV-2 virology increased, many potential drugs appeared. At this moment (January 12th 2021), 4426 studies of COVID-19 are registered, and more than 2680 studies are investigating therapeutic options. This is a short narrative review of currently available evidence on pharmacological treatment of COVID-19.\",\"PeriodicalId\":354348,\"journal\":{\"name\":\"Infektološki glasnik\",\"volume\":\"12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infektološki glasnik\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37797/ig.40.4.4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektološki glasnik","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37797/ig.40.4.4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Since the first cases of COVID-19 were reported from China the disease became pandemic within a few months. The viral genome was sequenced soon after the outbreak of COVID-19 which enabled development of diagnostic tests and therapeutic options. As the knowledge of SARS-CoV-2 virology increased, many potential drugs appeared. At this moment (January 12th 2021), 4426 studies of COVID-19 are registered, and more than 2680 studies are investigating therapeutic options. This is a short narrative review of currently available evidence on pharmacological treatment of COVID-19.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
